Vanda Pharmaceuticals Earnings: Here’s Why the Stock is Down Now

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) had a loss and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 2.33%.

Vanda Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.11 in the quarter versus EPS of $-0.28 in the year-earlier quarter.

Revenue: Decreased 0.72% to $8.32 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Vanda Pharmaceuticals, Inc. reported adjusted EPS loss of $0.11 per share. By that measure, the company beat the mean analyst estimate of $-0.22. It missed the average revenue estimate of $8.43 million.

Key Stats (on next page)…

Revenue decreased 0% from $0 in the previous quarter. EPS decreased to $-0.11 in the quarter versus EPS of $-0.15 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.23 to a loss $0.33. For the current year, the average estimate has moved down from a loss of $0.89 to a loss of $0.91 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]